

Simon Tanguay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/931846/publications.pdf>

Version: 2024-02-01

70
papers

1,529
citations

304743

22
h-index

345221

36
g-index

71
all docs

71
docs citations

71
times ranked

2453
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 66.e25-66.e31.	1.6	212
2	Multimodal Prehabilitation to Enhance Functional Capacity Following Radical Cystectomy: A Randomized Controlled Trial. <i>European Urology Focus</i> , 2021, 7, 132-138.	3.1	85
3	Prehabilitation for radical prostatectomy: A multicentre randomized controlled trial. <i>Surgical Oncology</i> , 2018, 27, 289-298.	1.6	83
4	Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes. <i>Urology</i> , 2016, 94, 154-160.	1.0	60
5	Safety, reliability and accuracy of small renal tumour biopsies: results from a multi-institution registry. <i>BJU International</i> , 2017, 119, 543-549.	2.5	56
6	A General Framework for Interrogation of mRNA Stability Programs Identifies RNA-Binding Proteins that Govern Cancer Transcriptomes. <i>Cell Reports</i> , 2018, 23, 1639-1650.	6.4	56
7	Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized Cohort. <i>European Urology</i> , 2020, 78, 460-467.	1.9	53
8	Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: Assessment of adequate renal function and influence on outcome. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 31.e17-31.e24.	1.6	49
9	Canadian guidelines for the management of the small renal mass (SRM). <i>Canadian Urological Association Journal</i> , 2015, 9, 160.	0.6	45
10	Growth kinetics of small renal masses: A prospective analysis from the Renal Cell Carcinoma Consortium of Canada. <i>Canadian Urological Association Journal</i> , 2014, 8, 24.	0.6	44
11	Postoperative mortality and complications after radical cystectomy for bladder cancer in Quebec: A population-based analysis during the years 2000-2009. <i>Canadian Urological Association Journal</i> , 2014, 8, 259.	0.6	44
12	Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: Results from the Canadian Upper Tract Collaboration. Co-first authors.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 839-845.	1.6	44
13	Factors influencing disease progression of prostate cancer under active surveillance: a multicenter cohort. <i>BJU International</i> , 2014, 114, E99-E104.	2.5	42
14	Cost-effectiveness of multiparametric magnetic resonance imaging and targeted biopsy in diagnosing prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 119.e1-119.e9.	1.6	39
15	The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 486.e1-486.e7.	1.6	37
16	Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative. <i>Canadian Urological Association Journal</i> , 2017, 11, 182.	0.6	33
17	The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature. <i>Human Pathology</i> , 2014, 45, 488-497.	2.0	31
18	Diagnosis and management of benign prostatic hyperplasia in primary care. <i>Canadian Urological Association Journal</i> , 2013, 3, 92.	0.6	30

#	ARTICLE	IF	CITATIONS
19	Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study. <i>World Journal of Urology</i> , 2016, 34, 1405-1409.	2.2	28
20	Enhanced recovery pathway for radical prostatectomy: Implementation and evaluation in a universal healthcare system. <i>Canadian Urological Association Journal</i> , 2014, 8, 418.	0.6	27
21	Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 738-741.	0.8	27
22	Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 486.e17-486.e23.	1.6	25
23	Impact of COVID-19 on medical education: introducing homo digitalis. <i>World Journal of Urology</i> , 2021, 39, 1997-2003.	2.2	22
24	Prioritising Urological Surgery in the COVID-19 Era: A Global Reflection on Guidelines. <i>European Urology Focus</i> , 2020, 6, 1104-1110.	3.1	20
25	Inverted urothelial carcinoma: a series of 12 cases with a wide morphologic spectrum overlapping with the large nested variant. <i>Human Pathology</i> , 2015, 46, 1506-1513.	2.0	18
26	Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 799.e1-799.e10.	1.6	18
27	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. <i>Canadian Urological Association Journal</i> , 2018, 12, 173-80.	0.6	16
28	Impact of COVID-19 on Urology Practice: A Global Perspective and Snapshot Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1730.	2.4	16
29	Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2018, 12, 231-238.	0.6	14
30	Determining Generalizability of the Canadian Kidney Cancer information system (CKCis) to the Entire Canadian Kidney Cancer Population. <i>Canadian Urological Association Journal</i> , 2020, 14, E499-E506.	0.6	13
31	Structured assessment and followup for patients with hereditary kidney tumour syndromes. <i>Canadian Urological Association Journal</i> , 2016, 10, 214.	0.6	12
32	A Multicentered, Propensity Matched Analysis Comparing Laparoscopic and Open Surgery for pT3a Renal Cell Carcinoma. <i>Journal of Endourology</i> , 2017, 31, 645-650.	2.1	12
33	Are basic robotic surgical skills transferable from the simulator to the operating room? A randomized, prospective, educational study. <i>Canadian Urological Association Journal</i> , 2020, 14, 416-422.	0.6	12
34	Evaluation of RNA-binding motif protein 3 expression in urothelial carcinoma of the bladder: an immunohistochemical study. <i>World Journal of Surgical Oncology</i> , 2015, 13, 317.	1.9	11
35	Acceptability and Usefulness of a Dyadic, Tailored, Web-Based, Psychosocial and Physical Activity Self-Management Program (TEMPO): A Qualitative Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3284.	2.4	11
36	Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma. <i>Journal of Urology</i> , 2021, 205, 78-85.	0.4	11

#	ARTICLE	IF	CITATIONS
37	Atypical tuberous sclerosis complex presenting as familial renal cell carcinoma with leiomyomatous stroma. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 167-174.	3.0	10
38	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2018, 13, 166-174.	0.6	10
39	External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2018, 36, 1973-1980.	2.2	10
40	Canadian Urological Association guideline: Management of small renal masses – Full-text. <i>Canadian Urological Association Journal</i> , 2021, 16, E61-75.	0.6	10
41	Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2017, 3, 105-112.	0.4	9
42	Prognostic significance of extent of venous tumor thrombus in patients with non-metastatic renal cell carcinoma: Results from a Canadian multi-institutional collaborative. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 836.e19-836.e27.	1.6	9
43	Clinical outcomes following laparoscopic management of pT3 renal masses: A large, multi-institutional cohort. <i>Canadian Urological Association Journal</i> , 2015, 9, 397.	0.6	8
44	Surgical Management of Stage T1 Renal Tumors in Canadian Academic Centers. <i>Canadian Urological Association Journal</i> , 2015, 9, 99.	0.6	8
45	Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective. <i>Canadian Urological Association Journal</i> , 2017, 11, 232-7.	0.6	8
46	Age-related variations in gene expression patterns of renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 166-175.	1.6	8
47	Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 521-530.	1.9	8
48	Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening. <i>BMC Urology</i> , 2018, 18, 69.	1.4	7
49	Making a case –against–focal therapy for intermediate-risk prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 719-728.	2.2	7
50	Rational Development of Liquid Biopsy Analysis in Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5825.	3.7	7
51	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of renal mass biopsy in the management of kidney cancer. <i>Canadian Urological Association Journal</i> , 2019, 13, 377-383.	0.6	6
52	Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy. <i>Human Pathology</i> , 2014, 45, 2006-2013.	2.0	5
53	Pathology review impacts clinical management of patients with T1–T2 bladder cancer. <i>Canadian Urological Association Journal</i> , 2017, 11, 188.	0.6	5
54	Management of complex renal cysts in Canada: results of a survey study. <i>BMC Urology</i> , 2020, 20, 47.	1.4	5

#	ARTICLE	IF	CITATIONS
55	Refining assessment of response to radiation-based therapy for muscle-invasive bladder cancer: Is post-treatment tumor bed biopsy always necessary?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 299.e7-299.e14.	1.6	5
56	Isolated peritoneal carcinomatosis from metastatic castration-resistant prostate cancer and associated biliary obstruction: A case report. <i>Urology Case Reports</i> , 2018, 21, 10-11.	0.3	4
57	Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 576.e11-576.e16.	1.6	3
58	Cross-continental comparison of safety and protection measures amongst urologists during COVID-19. <i>International Journal of Urology</i> , 2020, 27, 981-989.	1.0	3
59	Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma. <i>Practical Radiation Oncology</i> , 2022, 12, e34-e39.	2.1	3
60	Does transperitoneal minimally invasive radical prostatectomy increase the amount of small bowel receiving salvage radiation?. <i>Canadian Urological Association Journal</i> , 2013, 7, 444.	0.6	2
61	Changes in the levels of testosterone profile over time in relation to clinical parameters in a cohort of patients with prostate cancer managed by active surveillance. <i>World Journal of Urology</i> , 2018, 36, 1209-1217.	2.2	2
62	The increasing use of renal tumor biopsy amongst Canadian urologists: When is biopsy most utilized?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 499.e15-499.e22.	1.6	2
63	Ultrasound Correlates Highly With Cross Sectional Imaging for Small Renal Masses in a Contemporary Cohort. <i>Urology</i> , 2022, , .	1.0	2
64	A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers: Results from the Canadian Kidney Cancer Information System. <i>Journal of Urology</i> , 2022, 208, 804-812.	0.4	2
65	Health care services utilization during the last 6 months of life among patients with bladder cancer who underwent radical cystectomy in Quebec, Canada. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 539.e1-539.e7.	1.6	1
66	Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system. <i>Canadian Urological Association Journal</i> , 2020, 15, 132-137.	0.6	1
67	Adrenalectomy During Radical Nephrectomy- Incidence and Oncologic Outcomes From the Canadian Kidney Cancer Information System (CKCis) -A Modern Era, Nationwide, Multicenter Cohort. <i>Urology</i> , 2021, , .	1.0	1
68	Canadian Urological Association guideline: Management of small renal masses – Summary of recommendations. <i>Canadian Urological Association Journal</i> , 2021, 16, 24-5.	0.6	1
69	Age-Related Mental Health Consequences of COVID-19: A Global Perspective. <i>Société Internationale D'urologie Journal</i> , 2021, 2, 25-31.	0.4	0
70	Reply By Authors. <i>Journal of Urology</i> , 2021, 205, 84-85.	0.4	0